Drugs / Lu-XT033
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06081686 | Sep 2023 → Dec 2025 | prostate cancer | Sinotau Pharmaceutical Group | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-10-14 | Sinotau Pharmaceutical Group | Regulatory 新一代转移性前列腺癌PSMA靶向RLT药物的中国临床试验申请获受理 sinotau.com ↗
2022 年10月14日，先通医药研发的一类新药[ 177 Lu]Lu-XT033注射液临床试验申请获得受理。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-10-14 | Sinotau Pharmaceutical Group | 新一代转移性前列腺癌PSMA靶向RLT药物的中国临床试验申请获受理 sinotau.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lu-XT033 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06081686 ↗ |
| Route | Intravenous | “During dose verification phase,Patients received \[177Lu\]Lu-XT033 Injection 1.11Gbq（30mCi）/1.85Gbq（50mCi）intravenously every 8 weeks (+/- 1 week) for a maximum of 6 cycles.” NCT06081686 ↗ |